Answers are grounded in this paper and cite their sources.
Concerted efforts have been made by scientists over the last decades in elucidating the molecular mechanisms leading to myeloproliferative neoplasms. The identification of oncogenic mutations in signal transduction pathways revealed the role of specific pathways in inducing excessive proliferation of myeloid lineages. The subsequent development of mouse models carrying mutations found in patients proved that the aberrant activation of these specific pathways plays a crucial role in the pathology of myeloproliferative neoplasms. This led to the development of tyrosine kinase inhibitors for the treatment of patients.
No takes yet. Share an insight, caveat, or question.
Ogbonna et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: